Of note, both TGFB1 and STAT6 are well-known for their immune evasive roles in breast tumor microenvironment while STAT1 is proposed as a potential biomarker in breast cancer patients undergoing immune checkpoint therapy [34–36]. Here, STAT1 is linked to breast neoplasm.